Contribution: Industrial Research Assistance Program – Contributions to Firms
Qu Biologics Inc.
$153,855.00
Enhancing eradication of solid tumours using Site-Specific Immunomodulators and engineered cancer-specific T cells
FY 2018-19 · 2019-03-01
Summary
This project aims to generate preclinical data showing that solid tumours can be better accessed and targeted by CAR T cells when the Firm's proprietary platform immunotherapy, Site-Specific Immunomodulators (SSIs), are used in conjunction as neoadjuvant therapy.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Burnaby|Burnaby, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
842333817
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2019-03-01 | 2018-19 | $114,096.00 |
| 1 | 2019-03-01 | 2018-19 | $114,096.00 |
| 2 | 2019-03-01 | 2018-19 | $153,855.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 92 days. The total amended value is 39,759 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 92 jours. La valeur totale des modifications est de 39 759 dollars.
Agreement End Date
2020-01-31
Agreement Number
924855
Agreement Start Date
2019-03-01
Agreement Title
Enhancing eradication of solid tumours using Site-Specific Immunomodulators and engineered cancer-specific T cells
Agreement Title (French)
Améliorer l'éradication des tumeurs solides à l'aide d'immunomodulateurs spécifiques au site et de cellules CAR-T modifiées spécifiques au cancer
Agreement Type
Contribution
Agreement Value
$153,855.00
Amendment Date
2019-10-21
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This project aims to generate preclinical data showing that solid tumours can be better accessed and targeted by CAR T cells when the Firm's proprietary platform immunotherapy, Site-Specific Immunomodulators (SSIs), are used in conjunction as neoadjuvant therapy.
Description (French)
Ce projet vise à générer des données précliniques montrant que les tumeurs solides peuvent être plus accessibles et mieux ciblées par les cellules CAR-T lorsque les immunomodulateurs spécifiques au site, la plate-forme exclusive de l'entreprise, sont utilisés conjointement comme thérapie néoadjuvante.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Burnaby South
Federal Riding (French)
Burnaby-Sud
Federal Riding Number
59003
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
842333817
Recipient City
Burnaby|Burnaby
Recipient Country
CA
Recipient Legal Name
Qu Biologics Inc.
Recipient Postal Code
V5G 4X4
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2018-2019-Q4-924855
